ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Active Biotech Ab

Active Biotech Ab (0GQU)

2.85
0.00
(0.00%)
Cerrado 30 Diciembre 10:30AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
2.85
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
107,297
0.00 Rango del Día 0.00
2.85 Rango de 52 semanas 2.85
Capitalización de Mercado [m]
Precio Anterior
2.85
Precio de Apertura
-
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
826
Acciones en circulación
361,739,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-22.51
Beneficio por acción (BPA)
-0.13
turnover
-
Beneficio neto
-45.8M

Acerca de Active Biotech Ab

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Diversified
Sede
Lund, Swe
Fundado
1994
Active Biotech Ab is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0GQU. The last closing price for Active Biotech Ab was SEK2.85. Over the last year, Active Biotech Ab shares have traded in a share price range of SEK 2.85 to SEK 2.85.

Active Biotech Ab currently has 361,739,000 shares in issue. The market capitalisation of Active Biotech Ab is SEK1.03 billion. Active Biotech Ab has a price to earnings ratio (PE ratio) of -22.51.

0GQU Últimas noticias

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage Lund, June 1, 2022...

Annual General Meeting of Active Biotech AB

Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was...

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis   Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration...

Annual Report 2021 Active Biotech AB (publ)

Annual Report 2021 Active Biotech AB (publ) Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed...

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Active Biotech strengthens the patent protection for laquinimod in eye disorders Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office...

Active Biotech Interim Report Q1 2022

Active Biotech Interim Report Q1 2022 FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of...

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday...

Number of shares and votes in Active Biotech

Number of shares and votes in Active Biotech The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program...

Correction: Active Biotech Year End Report 2021

Correction: Active Biotech Year End Report 2021 The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The...

Active Biotech: Year End Report 2021

Active Biotech: Year End Report 2021 FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1002.852.852.8516672.85DE
4002.852.852.8525002.85DE
12002.852.852.858262.85DE
26002.852.852.853962.85DE
52002.852.852.852202.85DE
156002.852.852.854442.85DE
260002.852.852.856442.85DE

0GQU - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Active Biotech Ab?
El precio actual de las acciones de Active Biotech Ab es SEK 2.85
¿Cuántas acciones de Active Biotech Ab están en circulación?
Active Biotech Ab tiene 361,739,000 acciones en circulación
¿Cuál es la capitalización de mercado de Active Biotech Ab?
La capitalización de mercado de Active Biotech Ab es SEK 1.03B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Active Biotech Ab?
Active Biotech Ab ha negociado en un rango de SEK 2.85 a SEK 2.85 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Active Biotech Ab?
El ratio precio/beneficio de Active Biotech Ab es -22.51
¿Cuál es la moneda de reporte de Active Biotech Ab?
Active Biotech Ab presenta sus resultados financieros en SEK
¿Cuál es el último beneficio anual de Active Biotech Ab?
El último beneficio anual de Active Biotech Ab es SEK -45.8M
¿Cuál es la dirección registrada de Active Biotech Ab?
La dirección registrada de Active Biotech Ab es SCHEELEVAGEN 22, LUND, SE-223 63
¿Cuál es la dirección del sitio web de Active Biotech Ab?
La dirección del sitio web de Active Biotech Ab es www.activebiotech.com
¿En qué sector industrial opera Active Biotech Ab?
Active Biotech Ab opera en el sector PHARMACEUTICAL DIVERSIFIED

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CLAICel Ai Plc
0.085p
(41.67%)
20.31M
ZEDZenova Group Plc
0.675p
(22.73%)
3.96M
GFINGfinity Plc
0.07p
(21.74%)
109.16M
PRMProteome Sciences Plc
4.10p
(19.88%)
67.23k
VRCIVerici Dx Plc
3.875p
(19.23%)
679.37k
QUIZQuiz Plc
0.745p
(-15.82%)
5.25M
SRESSunrise Resources Plc
0.0275p
(-15.38%)
43.75M
PPSProton Motor Power Systems Plc
0.275p
(-15.38%)
401.8k
SYMESupply@me Capital Plc
0.0034p
(-13.92%)
511.77M
PREMPremier African Minerals Limited
0.044p
(-12.87%)
291.61M
TRPTower Resources Plc
0.037p
(8.82%)
983.58M
SYMESupply@me Capital Plc
0.0034p
(-13.92%)
511.77M
NTVONativo Resources Plc
0.002p
(0.00%)
399.34M
PREMPremier African Minerals Limited
0.044p
(-12.87%)
291.61M
CPXCap-xx Limited
0.1525p
(3.39%)
264.9M
Eagle1 Eagle1 14 segundos hace
Good Morning All, like this one too RVPH 1.8797 0.0797 (4.43%) 12-30-24
RVPH
GTF GTF 18 segundos hace
This mornings incredible post:
https://x.com/ABIntlGroup/status/1873748749572518301
ABQQ
Magnum7419 Magnum7419 19 segundos hace
wow talk about painting the tape............1 share,sold

nasd
10:05:52 0.0009 1 Sell 0.0009 0.001
AHRO
Wayne R Wayne R 33 segundos hace
Where there is life there is hope
bucks2pennies bucks2pennies 48 segundos hace
No report of O/S increase for some time now. 16.8B+ remains the same as of 12/23/24 per OTC
GTCH
threewheeler threewheeler 50 segundos hace
BOPO tax loss selling some body, and nothing we can do about buying these, talk about sux
BOPO
saj saj 1 minuto hace
Buru nice move today over .7
glenn1919 glenn1919 1 minuto hace
erna.......................https://stockcharts.com/h-sc/ui?s=erna&p=W&b=5&g=0&id=p86431144783
ERNA
jour_trader jour_trader 1 minuto hace
Also, the price will be for 30, 60 or 90 bottles so don't we need to take capsule production max of 57K per 8 hour shift and divide by at least 30? We'd then take this and apply it to about 50% of price we see on GoodRx for a reasonable estimate for Elite revenue after pharmacy, distributor & other
ELTP
prototype_101 prototype_101 1 minuto hace
Hero EXACTLY 💯 in addition to Leonberger buying up 100,000 options outright and disposing ZERO, a couple more things he could consider,

1) the latest round of Annual Incentive Comps were issued at $5 strike, and this was at a time the PPS was in 3's

2) the new C
LWLG
AJH92 AJH92 1 minuto hace
Update - December 30: "United States Citizenship and Immigration Services (USCIS) has released processing data for EB-5 visa petitions through Q4 FY2024. The data includes the filings, approvals, denials, and pending cases of Form I-526 legacy, I-526, and I-526E petition for regional center investor
PSRU
tw0122 tw0122 2 minutos hace
.90s +30%%
JDZG
DaJester DaJester 2 minutos hace
One other thing that I think you are misunderstanding: I think Treasury will end up with 80-99.9% of the final share count, i.e. after considering a junior-to-common conversion and capital raise.

I think this is the fundamental difference in theories. It's going to be exceedingly diff
FNMA
stockprofitter stockprofitter 2 minutos hace
He doesn’t work for the government
FNMA
Wayne R Wayne R 2 minutos hace
You sound like Dylan Hunt

https://g.co/kgs/8k8Q7aj
rosemountbomber rosemountbomber 2 minutos hace
They have been waiting for the new formulation to weave its way through the patent and FDA approval processes.

Do we know if they have actually started the approval process with the FDA? Isn't that material information that they would need to release?

Also, I like the
AMRN
tw0122 tw0122 2 minutos hace
.93
JDZG
dexprs dexprs 2 minutos hace
We may have seen the short term bottom this morning. I am changing my tactics accordingly and will be adding larger positions.
FFFacts FFFacts 2 minutos hace
Why do we only see positive statement gains but never losses from the dishonorably discharged?
FNMA
DewDiligence DewDiligence 2 minutos hace
It’s just under 10% of my overall investment portfolio, but it’s about 30% of the drug/biotech portion of my portfolio.
Trooperstocks Trooperstocks 2 minutos hace
$RELT - The acquisition began as early as March of 2023, but its more recent strategic transformation underscores ONAR's visionary drive to position the agency at the forefront of the healthcare marketing industry. As ONAR expands its expertise to new and emerging markets, Of Kos aligns with its rob
RELT
LowFloatLopes LowFloatLopes 2 minutos hace
Bye bye wall 
HOLO
Trooperstocks Trooperstocks 2 minutos hace
$RELT - The acquisition began as early as March of 2023, but its more recent strategic transformation underscores ONAR's visionary drive to position the agency at the forefront of the healthcare marketing industry. As ONAR expands its expertise to new and emerging markets, Of Kos aligns with its rob
RELT
Omar8 Omar8 3 minutos hace
AlwaysRed,





Dropping to fill those last contracts ?


https://www.cmegroup.com/markets/metals/precious/silver.volume.html
SLV
barttt barttt 3 minutos hace
What is our market cap now?  Seems pretty low for owning a 20mil revenue/year furniture company 
ASKH